Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Vera EhrensteinKui HuangJohnny KahlertShahram BahmanyarPär KarlssonL Lukas LøflingAnthony P NunesCheryl EngerIrene D BezemerJosephina G KuiperFabian HotiRosa JuutiPasi KorhonenJingping MoStephen E SchachterleKeith D WilnerMikael RørthHenrik T SørensenPublished in: Pharmacoepidemiology and drug safety (2021)
This study describes clinical outcomes among lung cancer patients initiating crizotinib or erlotinib in routine clinical practice. Differences between SOI rates in EU and US may be partially attributable to differences in the underlying databases.